Diversify Wealth Management LLC Acquires 304 Shares of STERIS plc (NYSE:STE)

Diversify Wealth Management LLC grew its holdings in shares of STERIS plc (NYSE:STE) by 7.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,222 shares of the medical equipment provider’s stock after buying an additional 304 shares during the period. Diversify Wealth Management LLC’s holdings in STERIS were worth $934,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Massachusetts Financial Services Co. MA boosted its holdings in shares of STERIS by 13.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock valued at $1,414,453,000 after buying an additional 778,613 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in STERIS by 7.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider’s stock worth $390,880,000 after purchasing an additional 120,616 shares in the last quarter. Sustainable Growth Advisers LP boosted its stake in STERIS by 23.5% in the 1st quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock worth $333,988,000 after purchasing an additional 282,387 shares in the last quarter. Impax Asset Management Group plc boosted its stake in STERIS by 29.7% in the 2nd quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock worth $251,663,000 after purchasing an additional 263,383 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in STERIS by 0.9% in the 2nd quarter. Principal Financial Group Inc. now owns 1,017,888 shares of the medical equipment provider’s stock worth $223,467,000 after purchasing an additional 8,601 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on STE shares. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. StockNews.com cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. JMP Securities reissued a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Finally, Stephens reissued an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.00.

Insider Activity

In other news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Christopher S. Holland sold 473 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares of the company’s stock, valued at approximately $139,493.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

STERIS Price Performance

Shares of NYSE:STE opened at $224.42 on Thursday. STERIS plc has a fifty-two week low of $195.47 and a fifty-two week high of $248.24. The business has a 50-day simple moving average of $234.38 and a two-hundred day simple moving average of $226.73. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33. The firm has a market cap of $22.13 billion, a price-to-earnings ratio of 55.69 and a beta of 0.84.

STERIS (NYSE:STE) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating the consensus estimate of $1.98 by $0.16. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.27 billion. During the same quarter in the prior year, the firm earned $2.00 EPS. The business’s revenue for the quarter was down .4% compared to the same quarter last year. On average, analysts expect that STERIS plc will post 9.06 earnings per share for the current year.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.